Quantcast

Latest tumor Stories

2014-09-16 20:27:34

-- PEG-Irinotecan is a novel, long-acting polymer-drug conjugate which inhibits Topo-I associated with solid tumors SHENYANG, China, Sept. 16, 2014 /PRNewswire/ -- 3SBio Inc., ("3SBio") a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd ("JenKem") for the development, manufacturing and...

2014-09-15 08:29:42

REDWOOD CITY, Calif., Sept. 15, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, today announced that it has received accreditation by the College of American Pathologists (CAP) based on results of a recent on-site laboratory inspection. The laboratory, based in Redwood City, is the leader in providing non-invasive, pan-cancer tumor genome sequencing with a simple blood draw. This...

2014-09-15 08:29:25

Unusually broad range of tumors treated, other benefits seen in first seven months SAN FRANCISCO, Sept. 15, 2014 /PRNewswire/ -- The nation's first proton therapy center to treat patients exclusively with pencil-beam scanning is reporting exceptional results in delivering cancer treatment since opening for patient care in February. Carl Rossi, M.D., medical director of the Scripps Proton Therapy Center in San Diego, offered the assessment in San Francisco, where the American Society...

2014-09-14 23:00:36

A study led by University of Colorado Cancer Center published today in the journal Nature uses a novel approach to target the activation of a protein that drives some cancers. AURORA, Colo. (PRWEB) September 14, 2014 When active, the protein called Ral can drive tumor growth and metastasis in several human cancers including pancreatic, prostate, lung, colon and bladder. Unfortunately, drugs that block its activity are not available. A study published today in the journal Nature uses a...

2014-09-10 12:27:54

ViewRay's MRIdian System Directly Tracks Tumor Motion Continuously During Treatment CLEVELAND, Sept. 10, 2014 /PRNewswire/ -- The MRIdian(TM) (me-rid-i-an) system from ViewRay(TM), a privately held medical device company, is now being used to treat patients at the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, the second clinical group in the world to treat patients with MRI-guided radiation therapy. With yesterday's treatment, the center also became the first...

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...

2014-09-08 08:30:26

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8(th) International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD,...

2014-09-03 23:05:54

Global research initiative to investigate long-term glioblastoma survivors. Chicago, IL (PRWEB) September 03, 2014 The American Brain Tumor Association (ABTA), in conjunction with the Brain Tumor Funder’s Collaborative (BTFC), is awarding a $2 million research grant to explore commonalities among long-term glioblastoma survivors around the world. Glioblastoma is a common and aggressive type of brain tumor most prevalent in adults ages 45-65, and affects more men than women. This highly...

2014-09-01 16:21:50

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Marketshttps://www.reportbuyer.com/product/2009162/Circulating-Tumor-Cell-CTC-Diagnostics-Technologies-and-Global-Markets.html STUDY GOALS AND OBJECTIVESThis report, PHM153A - Circulating Tumor Cell (CTC) Diagnostic: Technologies and Global Markets, gives market insight on monitoring tests used for cancer prognoses. The...

2014-08-31 23:02:00

Doctors at Atlantic NeuroSurgical Specialists (ANS) have added a new and innovative form of therapy to their treatment arsenal in the battle against glioblastoma multiforme (GBM). Affecting nearly 10,000 Americans annually, GBM is the one of the most aggressive and difficult-to-control forms of primary brain tumors in the United States. Morristown, NJ (PRWEB) August 31, 2014 Describing the NovoTTFTM system as a “cell division taser device,” Dr. Yaron Moshel explains that the NovoTTF...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'